<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ymj</journal-id><journal-title-group><journal-title xml:lang="ru">Якутский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Yakut Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1813-1905</issn><issn pub-type="epub">2312-1017</issn><publisher><publisher-name>ЯНЦ КМП</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.25789/YMJ.2023.82.22</article-id><article-id custom-type="elpub" pub-id-type="custom">ymj-201</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НАУЧНЫЕ ОБЗОРЫ И ЛЕКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SCIENTIFIC REVIEWS AND LECTURES</subject></subj-group></article-categories><title-group><article-title>Эндотелиопротекторные функции липопротеинов высокой плотности</article-title><trans-title-group xml:lang="en"><trans-title>Endothelial protective functions of high density lipoproteins</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1068-2431</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Потеряева</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Poteryaeva</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ольга Николаевна Потеряева, д. м. н., в. н. с.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Novosibirsk</p></bio><email xlink:type="simple">olga_Poteryaeva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1752-9034</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Усынин</surname><given-names>И. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Usynin</surname><given-names>I. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иван Фёдорович Усынин, д. б. н., зав. лаб.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Novosibirsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НИИ биохимии ФИЦ фундаментальной и трансляционной медицины</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Biochemistry of the Federal Research Center for Fundamental and Translational Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>05</day><month>02</month><year>2025</year></pub-date><volume>0</volume><issue>2</issue><fpage>90</fpage><lpage>95</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Потеряева О.Н., Усынин И.Ф., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Потеряева О.Н., Усынин И.Ф.</copyright-holder><copyright-holder xml:lang="en">Poteryaeva O.N., Usynin I.F.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://ymj.elpub.ru/jour/article/view/201">https://ymj.elpub.ru/jour/article/view/201</self-uri><abstract><p>   Цель обзора – дать современные представления об участии липопротеинов высокой плотности (ЛПВП) в функционировании эндотелиальных клеток и предотвращении развития эндотелиальной дисфункции.</p><p>   Связываясь с различными рецепторами на эндотелиальных клетках, ЛПВП вызывают индукцию эндотелиальной синтазы оксида азота, повышают продукцию NO, стимулируют синтез простациклина, что приводит к снижению тонуса сосудов. Подавляя синтез молекул межклеточной адгезии, ЛПВП предотвращают миграцию лейкоцитов и моноцитов/макрофагов в сосудистую стенку, оказывая противовоспалительное действие. ЛПВП ингибируют продукцию активных форм кислорода, предотвращают апоптоз, стимулируют пролиферацию и миграцию эндотелиальных клеток.</p></abstract><trans-abstract xml:lang="en"><p>   The goal of this review is to describe modern concepts concerning the involvement of HDLs in the functioning of endothelial cells and preventing the development of endothelial dysfunction.</p><p>   Upon binding to various receptors on endothelial cells, HDLs initiate the induction of endothelial nitric oxide synthase, enhance the production of NO, and stimulate the synthesis of prostacyclin, thus leading to vasorelaxation. By suppressing the synthesis of intercellular adhesion molecules, HDLs prevent the migration of leucocytes and monocytes/macrophages into the vascular wall, exerting anti-inflammatory action. HDLs inhibit the production of reactive oxygen species, prevent apoptosis, and stimulate the proliferation and migration of endothelial cells.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>эндотелиальные клетки</kwd><kwd>липопротеины высокой плотности</kwd><kwd>апоптоз</kwd><kwd>ангиогенез</kwd><kwd>сердечно-сосудистые заболевания</kwd></kwd-group><kwd-group xml:lang="en"><kwd>endothelial cells</kwd><kwd>high density lipoproteins</kwd><kwd>apoptosis</kwd><kwd>angiogenesis</kwd><kwd>cardiovascular diseases</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках государственного задания Министерства науки и высшего образования Российской Федерации (регистрационный номер темы 1021050400914-1-1.6.4)</funding-statement><funding-statement xml:lang="en">The work was carried out within the framework of the state assignment of the Ministry of Science and Higher Education Of the Russian Federation (registration number of the topic 1021050400914-1-1.6.4)</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Перова Н.В. Атеромаркеры липопротеинов высокой плотности. Ч. II. Липопротеины высокой плотности: структура, состав, физико-химические и физиологические антиатерогенные свойства, их механизмы и маркеры (обзор литературы)// Профилакт. медицина. 2017; 20(4): 37-44. DOI: 10.17116/profmed201720437-44</mixed-citation><mixed-citation xml:lang="en">Perova N.V. Atheromarkers of high-density lipoproteins. Part II. High-density lipoproteins: structure, composition, physicochemical and physiological antiatherogenic properties, their mechanisms and markers (a review of literature) // The Russian Journal of Preventive Medicine. 2017; 20(4): 37-44. DOI: 10.17116/profmed201720437-44</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Роль кавеол и кавеолина в норме и патологии / Р.И. Воробъёв, Г.И. Шумахер, М.А., Хорева [и др.] // Кардиоваскулярная терапия и профилактика. 2008; 7(8): 105-111.</mixed-citation><mixed-citation xml:lang="en">The role of caveolae and caveolin in health and disease / R.I. Vorobiev, G.I. Shumakher, M.A. Khoreva [et al.] // Cardiovascular Therapy and Prevention. 2008; 7(8): 105-111.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Роль сахарного диабета в возникновении и развитии эндотелиальной дисфункции / Э. Б. Попыхова, Т.В. Степанова, Д.Д. Лагутина [и др.] // Проблемы эндокринологии. 2020; 66(1): 47-55. DOI: 10.14341/probl12212</mixed-citation><mixed-citation xml:lang="en">The role of diabetes in the onset and development of endothelial dysfunction / E.B. Popyhova, T.V.Stepanova, D.D. Lagutina [et al.] // Problems of Endocrinology. 2020; 66(1): 47-55. DOI: 10.14341/probl12212</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Antioxidative activity of high-density lipoprotein (HDL): mechanistic insights into potential clinical benefit / F. Brites, M. Martin, I. Guillas [et al.] // BBA Clin. 2017; 8: 66–77. DOI:10.1016/j.bbacli.2017.07.002.</mixed-citation><mixed-citation xml:lang="en">Antioxidative activity of high-density lipoprotein (HDL): mechanistic insights into potential clinical benefit / F. Brites, M. Martin, I. Guillas [et al.] // BBA Clin. 2017; 8: 66–77. DOI:10.1016/j.bbacli.2017.07.002.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">An involvement of SR-B1 mediated PI3K-Akt-eNOS signaling in HDL-induced cyclooxygenase 2 expression and prostacyclin production in endothelial cells / Q-H. Zhang, X-Y. Zu, R-X. Cao [et al.] // Biochem Biophys Res Commun. 2012; 420(1): 17–23. DOI: 10.1016/j.bbrc.2012.02.103.</mixed-citation><mixed-citation xml:lang="en">An involvement of SR-B1 mediated PI3K-Akt-eNOS signaling in HDL-induced cyclooxygenase 2 expression and prostacyclin production in endothelial cells / Q-H. Zhang, X-Y. Zu, R-X. Cao [et al.] // Biochem Biophys Res Commun. 2012; 420(1): 17–23. DOI: 10.1016/j.bbrc.2012.02.103.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">A novel anti-inflammatory mechanism of high density lipoprotein through up-regulating annexin A1 in vascular endothelial cells / B. Pan, J. Kong, J. Jin [et al.] // BBA - Molecular and Cell Biology of Lipids. 2016; 1861(6): 501–512. DOI: 10.1016/j.bbalip.2016.03.022</mixed-citation><mixed-citation xml:lang="en">A novel anti-inflammatory mechanism of high density lipoprotein through up-regulating annexin A1 in vascular endothelial cells / B. Pan, J. Kong, J. Jin [et al.] // BBA - Molecular and Cell Biology of Lipids. 2016; 1861(6): 501–512. DOI: 10.1016/j.bbalip.2016.03.022</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Apolipoprotein A-1 mimetic peptide 4F promotes endothelial repairing and compromises reendothelialization impaired by oxidized HDL through SR-B1 / D. He, M. Zhao, C. Wu [et al.] // Redox Biol. 2018; 15: 228–242. DOI: 10.1016/j.redox.2017.11.027</mixed-citation><mixed-citation xml:lang="en">Apolipoprotein A-1 mimetic peptide 4F promotes endothelial repairing and compromises reendothelialization impaired by oxidized HDL through SR-B1 / D. He, M. Zhao, C. Wu [et al.] // Redox Biol. 2018; 15: 228–242. DOI: 10.1016/j.redox.2017.11.027</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Apolipoprotein A-I improves pancreatic β-cell function independent of the ATP-binding cassette transporters ABCA1 and ABCG1 / L. Hou, S. Tang, BJ. Wu [et al.] // FASEB J. 2019; 33(7): 8479-8489. DOI: 10.1096/fj.201802512RR.</mixed-citation><mixed-citation xml:lang="en">Apolipoprotein A-I improves pancreatic β-cell function independent of the ATP-binding cassette transporters ABCA1 and ABCG1 / L. Hou, S. Tang, BJ. Wu [et al.] // FASEB J. 2019; 33(7): 8479-8489. DOI: 10.1096/fj.201802512RR.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">ApoA1: a protein with multiple therapeutic functions / BJ. Cochran, KL. Ong, B. Manandhar [et al.] // Curr Atheroscler Rep. 2021; 23(3):11. DOI: 10.1007/s11883-021-00906-7.</mixed-citation><mixed-citation xml:lang="en">ApoA1: a protein with multiple therapeutic functions / BJ. Cochran, KL. Ong, B. Manandhar [et al.] // Curr Atheroscler Rep. 2021; 23(3):11. DOI: 10.1007/s11883-021-00906-7.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Apolipoprotein M-bound sphin-gosine1-phosphate regulates blood-brain barrier paracellular permeability and transcytosis / M. Mathiesen Janiurek, R. Soylu-Kucharz, C. Christoffersen [et al.] // Elife. 2019; 8: e49405. DOI: 10.7554/eLife.49405.</mixed-citation><mixed-citation xml:lang="en">Apolipoprotein M-bound sphin-gosine1-phosphate regulates blood-brain barrier paracellular permeability and transcytosis / M. Mathiesen Janiurek, R. Soylu-Kucharz, C. Christoffersen [et al.] // Elife. 2019; 8: e49405. DOI: 10.7554/eLife.49405.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Apolipoprotein A-I attenuates LL-37-induced endothelial cell cytotoxicity / D. Svensson, J.O. Lagerstedt, B-O. Nilsson [et al.] Biochem Biophys Res Commun. 2017; 493(1): 71-76. DOI: 10.1016/j.bbrc.2017.09.072</mixed-citation><mixed-citation xml:lang="en">Apolipoprotein A-I attenuates LL-37-induced endothelial cell cytotoxicity / D. Svensson, J.O. Lagerstedt, B-O. Nilsson [et al.] Biochem Biophys Res Commun. 2017; 493(1): 71-76. DOI: 10.1016/j.bbrc.2017.09.072</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Apolipoprotein A-I enhances proliferation of human endothelial progenitor cells and promotes angiogenesis through the cell surface ATP synthase / V. Gonzalez-Pecchi, S. Valdes, V. Pons [et al.] // Microvasc Res. 2015; 98: 9–15. DOI: 10.1016/j.mvr.2014.11.003</mixed-citation><mixed-citation xml:lang="en">Apolipoprotein A-I enhances proliferation of human endothelial progenitor cells and promotes angiogenesis through the cell surface ATP synthase / V. Gonzalez-Pecchi, S. Valdes, V. Pons [et al.] // Microvasc Res. 2015; 98: 9–15. DOI: 10.1016/j.mvr.2014.11.003</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Apolipoprotein A-I mimetic peptide reverses impaired arterial healing after injury by reducing oxidative stress / M.A. Rosenbaum, P. Chaudhuri, B. Abelson [et al.] // Atherosclerosis. 2015; 241(2): 709-715. DOI: 10.1016/j.atherosclerosis.2015.06.018</mixed-citation><mixed-citation xml:lang="en">Apolipoprotein A-I mimetic peptide reverses impaired arterial healing after injury by reducing oxidative stress / M.A. Rosenbaum, P. Chaudhuri, B. Abelson [et al.] // Atherosclerosis. 2015; 241(2): 709-715. DOI: 10.1016/j.atherosclerosis.2015.06.018</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">ATPbinding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase / N. Terasaka, M. Westerterp, J. Koetsveld [et al.] // Arter Thromb Vasc Biol. 2010; 30(11): 2219–2225. DOI: 10.1161/ATVBAHA.110.213215.</mixed-citation><mixed-citation xml:lang="en">ATPbinding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase / N. Terasaka, M. Westerterp, J. Koetsveld [et al.] // Arter Thromb Vasc Biol. 2010; 30(11): 2219–2225. DOI: 10.1161/ATVBAHA.110.213215.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Barter PJ, Rye KA. Targeting high-density lipoproteins to reduce cardiovascular risk: what is the evidence? Clin Ther. 2015; 37(12): 2716-2731. DOI: 10.1016/j.clinthera.2015.07.021.</mixed-citation><mixed-citation xml:lang="en">Barter PJ, Rye KA. Targeting high-density lipoproteins to reduce cardiovascular risk: what is the evidence? Clin Ther. 2015; 37(12): 2716-2731. DOI: 10.1016/j.clinthera.2015.07.021.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">D-4F induces hemeoxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes / AL. Kruger, S. Peterson, P. Turkseven [et al.] // Circulation. 2005; 111(23): 3126-3134. DOI: 10.1161/CIRCULATIONAHA.104.517102</mixed-citation><mixed-citation xml:lang="en">D-4F induces hemeoxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes / AL. Kruger, S. Peterson, P. Turkseven [et al.] // Circulation. 2005; 111(23): 3126-3134. DOI: 10.1161/CIRCULATIONAHA.104.517102</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">D-4F Ameliorates Contrast Media-Induced Oxidative Injuries in Endothelial Cells via the AMPK/PKC Pathway / Y. Guo, W. Li, M. Qian [et al.] // Front Pharmacol. 2021; 11:556074. DOI: 10.3389/fphar.2020.556074.</mixed-citation><mixed-citation xml:lang="en">D-4F Ameliorates Contrast Media-Induced Oxidative Injuries in Endothelial Cells via the AMPK/PKC Pathway / Y. Guo, W. Li, M. Qian [et al.] // Front Pharmacol. 2021; 11:556074. DOI: 10.3389/fphar.2020.556074.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet / J. Ou, J. Wang, H. Xu [et al.] / Circ Res. 2005; 97(11): 1190-1197. DOI: 10.1161/01.RES.0000190634.60042</mixed-citation><mixed-citation xml:lang="en">Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet / J. Ou, J. Wang, H. Xu [et al.] / Circ Res. 2005; 97(11): 1190-1197. DOI: 10.1161/01.RES.0000190634.60042</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Garbuzova-Davis S, Willing AE, Borlongan CV. Apolipoprotein A1 enhances endothelial cell survival in an in vitro model of ALS. ENEURO. 2022; 9(4): 0140-22.2022 1–11. DOI: 10.1523/ENEURO.0140-22.2022</mixed-citation><mixed-citation xml:lang="en">Garbuzova-Davis S, Willing AE, Borlongan CV. Apolipoprotein A1 enhances endothelial cell survival in an in vitro model of ALS. ENEURO. 2022; 9(4): 0140-22.2022 1–11. DOI: 10.1523/ENEURO.0140-22.2022</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Jackson AO, Rahman GA, Long S. Apolipoprotein-AI and AIBP synergetic anti-inflammation as vascular diseases therapy: the new perspective. Mol Cell Biochem. 2021; 476(8): 3065–3078. DOI: 10.1007/s11010-020-04037-6</mixed-citation><mixed-citation xml:lang="en">Jackson AO, Rahman GA, Long S. Apolipoprotein-AI and AIBP synergetic anti-inflammation as vascular diseases therapy: the new perspective. Mol Cell Biochem. 2021; 476(8): 3065–3078. DOI: 10.1007/s11010-020-04037-6</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jomard A, Osto E. High density lipoprotein: metabolism, function, and therapeutic potential. Front Cardiovasc Med. 2020; 7(39):1-12. DOI: 10.3389/fcvm.2020.00039.</mixed-citation><mixed-citation xml:lang="en">Jomard A, Osto E. High density lipoprotein: metabolism, function, and therapeutic potential. Front Cardiovasc Med. 2020; 7(39):1-12. DOI: 10.3389/fcvm.2020.00039.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">High-density lipoprotein antiinflammatory capacity and incident cardiovascular events / C. Jia, J.L.C. Anderson, E.G. Gruppen [et al.] // Circulation. 2021; 143(20): 1935-1945. DOI: 10.1161/CIRCULATIONAHA.120.050808</mixed-citation><mixed-citation xml:lang="en">High-density lipoprotein antiinflammatory capacity and incident cardiovascular events / C. Jia, J.L.C. Anderson, E.G. Gruppen [et al.] // Circulation. 2021; 143(20): 1935-1945. DOI: 10.1161/CIRCULATIONAHA.120.050808</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">High-density lipoprotein (HDL) promotes angiogenesis via S1P3-dependent VEGFR2 activation / F. Jin, N. Hagemann, L. Sun [et al.] // Angiogenesis 2018; 21(2): 381-394. DOI: 10.1007/s10456-018-9603-z</mixed-citation><mixed-citation xml:lang="en">High-density lipoprotein (HDL) promotes angiogenesis via S1P3-dependent VEGFR2 activation / F. Jin, N. Hagemann, L. Sun [et al.] // Angiogenesis 2018; 21(2): 381-394. DOI: 10.1007/s10456-018-9603-z</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation / B.G. Drew, N.H. Fidge, G. Gallon-Beaumie [et al.] // Proc Natl Acad Sci. USA. 2004; 101: 6999 - 7004. DOI: 10.1073/pnas.0306266101</mixed-citation><mixed-citation xml:lang="en">High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation / B.G. Drew, N.H. Fidge, G. Gallon-Beaumie [et al.] // Proc Natl Acad Sci. USA. 2004; 101: 6999 - 7004. DOI: 10.1073/pnas.0306266101</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells / G.D. Norata, E. Callegari, M. Marchesi [et al.] // Circulation. 2005;111: 2805–2811</mixed-citation><mixed-citation xml:lang="en">High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells / G.D. Norata, E. Callegari, M. Marchesi [et al.] // Circulation. 2005;111: 2805–2811</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3 / J.R. Nofer, M. van der Giet, M. Tolle [et al.] // J Clin Invest. 2004; 113(4): 569 – 581. DOI: 10.1172/JCI18004.</mixed-citation><mixed-citation xml:lang="en">HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3 / J.R. Nofer, M. van der Giet, M. Tolle [et al.] // J Clin Invest. 2004; 113(4): 569 – 581. DOI: 10.1172/JCI18004.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I / D. Seetharam, C. Mineo, A.K. Gormley [et al.] // Circ Res. 2006; 98(1): 63-72. DOI: 10.1161/01.RES.0000199272.59432.5b.</mixed-citation><mixed-citation xml:lang="en">High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I / D. Seetharam, C. Mineo, A.K. Gormley [et al.] // Circ Res. 2006; 98(1): 63-72. DOI: 10.1161/01.RES.0000199272.59432.5b.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">High-density lipoproteins rescue diabetes-impaired angiogenesis via scavenger receptor class B type I / J.T. Tan, H.C. Prosser, L.L. Dunn [et al.] // Diabetes. 2016; 65(10): 3091–3103. DOI: 10.2337/db15-1668</mixed-citation><mixed-citation xml:lang="en">High-density lipoproteins rescue diabetes-impaired angiogenesis via scavenger receptor class B type I / J.T. Tan, H.C. Prosser, L.L. Dunn [et al.] // Diabetes. 2016; 65(10): 3091–3103. DOI: 10.2337/db15-1668</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">HDL therapy today: from atherosclerosis, to stent compatibility to heart failure / C.R. Sirtori, M. Ruscica, L. Calabresi [et al.] // Ann Med. 2019; 51(7-8): 345-359. DOI: 10.1080/07853890.2019.1694695</mixed-citation><mixed-citation xml:lang="en">HDL therapy today: from atherosclerosis, to stent compatibility to heart failure / C.R. Sirtori, M. Ruscica, L. Calabresi [et al.] // Ann Med. 2019; 51(7-8): 345-359. DOI: 10.1080/07853890.2019.1694695</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">HDL-apoA-I induces the expression of angiopoietin like 4 (ANGPTL4) in endothelial cells via a PI3K/AKT/FOXO1 signaling pathway / D. Theofilatos, P. Fotakis, E. Valanti [et al.] // Metabolism. 2018; 87: 36–47. DOI: 10.1016/j.metabol.2018.06.002</mixed-citation><mixed-citation xml:lang="en">HDL-apoA-I induces the expression of angiopoietin like 4 (ANGPTL4) in endothelial cells via a PI3K/AKT/FOXO1 signaling pathway / D. Theofilatos, P. Fotakis, E. Valanti [et al.] // Metabolism. 2018; 87: 36–47. DOI: 10.1016/j.metabol.2018.06.002</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Impaired endothelial barrier function in apolipoprotein M-deficient mice is dependent on sphingosine-1-phosphate receptor 1 / P.M. Christensen, C.H. Liu, S.L. Swendeman [et al.] // FASEB J. 2016; 30(6): 2351–2359. DOI: 10.1096/fj.201500064</mixed-citation><mixed-citation xml:lang="en">Impaired endothelial barrier function in apolipoprotein M-deficient mice is dependent on sphingosine-1-phosphate receptor 1 / P.M. Christensen, C.H. Liu, S.L. Swendeman [et al.] // FASEB J. 2016; 30(6): 2351–2359. DOI: 10.1096/fj.201500064</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells / T. Kimura, C. Mogi, H. Tomura [et al.] // J Immunol. 2008; 181: 7332–7340. DOI: 10.4049/jimmunol.181.10.7332</mixed-citation><mixed-citation xml:lang="en">Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells / T. Kimura, C. Mogi, H. Tomura [et al.] // J Immunol. 2008; 181: 7332–7340. DOI: 10.4049/jimmunol.181.10.7332</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez-Gonzalez J, Escudero I, Badimon L. Simvastatin potenciates PGI(2) release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL. Atherosclerosis. 174(2): 305-313. DOI: 10.1016/j.atherosclerosis.2004.01.037174.</mixed-citation><mixed-citation xml:lang="en">Martinez-Gonzalez J, Escudero I, Badimon L. Simvastatin potenciates PGI(2) release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL. Atherosclerosis. 174(2): 305-313. DOI: 10.1016/j.atherosclerosis.2004.01.037174.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Mechanism and role of high density lipoprotein-induced activation of AMP-activated protein kinase in endothelial cells / T. Kimura, H. Tomura, K. Sato [et al] // J Biol Chem. 2010; 285(7): 4387-4397. DOI: 10.1074/jbc.M109.043869</mixed-citation><mixed-citation xml:lang="en">Mechanism and role of high density lipoprotein-induced activation of AMP-activated protein kinase in endothelial cells / T. Kimura, H. Tomura, K. Sato [et al] // J Biol Chem. 2010; 285(7): 4387-4397. DOI: 10.1074/jbc.M109.043869</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Mineo C, Shaul PW. Regulation of signal transduction by HDL. J Lipid Res. 2013; 54(9):2315–24. DOI: 10.1194/jlr.R039479</mixed-citation><mixed-citation xml:lang="en">Mineo C, Shaul PW. Regulation of signal transduction by HDL. J Lipid Res. 2013; 54(9):2315–24. DOI: 10.1194/jlr.R039479</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Mineo C. Lipoprotein receptor signalling in atherosclerosis. Cardiovasc Res. 2019; 116(7):1254-1274. DOI: 10.1093/cvr/cvz338.</mixed-citation><mixed-citation xml:lang="en">Mineo C. Lipoprotein receptor signalling in atherosclerosis. Cardiovasc Res. 2019; 116(7):1254-1274. DOI: 10.1093/cvr/cvz338.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Nofer JR. Signal transduction by HDL: Agonists, receptors, and signaling cascades. Handb. Exp. Pharmacol. /A. von Eckardstein, D. Kardassis (eds.) 2014; 224: 229–256. DOI: 10.1007/978-3-319-09665-0_6</mixed-citation><mixed-citation xml:lang="en">Nofer JR. Signal transduction by HDL: Agonists, receptors, and signaling cascades. Handb. Exp. Pharmacol. /A. von Eckardstein, D. Kardassis (eds.) 2014; 224: 229–256. DOI: 10.1007/978-3-319-09665-0_6</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Pharmacological inhibition of the F1-AT-Pase/P2Y1 pathway suppresses the effect of apolipoprotein A1 on endothelial nitric oxide synthesis and vasorelaxation / C. Cabou, P. Honorato, L. Briceño [et al.] // Acta Physiol. 2019; 226(3): e13268. DOI: 10.1111/apha.13268</mixed-citation><mixed-citation xml:lang="en">Pharmacological inhibition of the F1-AT-Pase/P2Y1 pathway suppresses the effect of apolipoprotein A1 on endothelial nitric oxide synthesis and vasorelaxation / C. Cabou, P. Honorato, L. Briceño [et al.] // Acta Physiol. 2019; 226(3): e13268. DOI: 10.1111/apha.13268</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Poteryaeva O.N., Usynin I.F. Antidiabetic role of high density lipoproteins. Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry. 2019; 13(2): 113-21. DOI: 10.1134/S1990750819020070</mixed-citation><mixed-citation xml:lang="en">Poteryaeva O.N., Usynin I.F. Antidiabetic role of high density lipoproteins. Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry. 2019; 13(2): 113-21. DOI: 10.1134/S1990750819020070</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Reciprocal multifaceted interaction between HDL (high-density lipoprotein) and myocardial infarction / A.C. Sposito, J.C. de Lima-Junior, F.A. Moura [et al.] Arterioscler Thromb Vasc Biol. 2019; 39(8): 1550–1564. DOI:10.1161/atvbaha.119.312880</mixed-citation><mixed-citation xml:lang="en">Reciprocal multifaceted interaction between HDL (high-density lipoprotein) and myocardial infarction / A.C. Sposito, J.C. de Lima-Junior, F.A. Moura [et al.] Arterioscler Thromb Vasc Biol. 2019; 39(8): 1550–1564. DOI:10.1161/atvbaha.119.312880</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein / R.J. Bisoendial, R.J. Bisoendial, G. Kees [et al.] // Circulation. 2003; 107(23): 2944–2948. doi: 10.1161/01.cir.0000070934.69310.1a</mixed-citation><mixed-citation xml:lang="en">Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein / R.J. Bisoendial, R.J. Bisoendial, G. Kees [et al.] // Circulation. 2003; 107(23): 2944–2948. doi: 10.1161/01.cir.0000070934.69310.1a</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Riwanto M, Rohrer L, von Eckardstein A. Dysfunctional HDL: From Structure function-relationships to biomarkers /A. von Eckardstein, D. Kardassis (eds.), High Density Lipoproteins, Handbook of Experimental Pharmacology. 2015; 224. DOI: 10.1007/978-3-319-09665-0_10</mixed-citation><mixed-citation xml:lang="en">Riwanto M, Rohrer L, von Eckardstein A. Dysfunctional HDL: From Structure function-relationships to biomarkers /A. von Eckardstein, D. Kardassis (eds.), High Density Lipoproteins, Handbook of Experimental Pharmacology. 2015; 224. DOI: 10.1007/978-3-319-09665-0_10</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Robert J, Osto E, von Eckardstein A. The endothelium is both a target and a barrier of HDL’s protective functions. Cells. 2021; 10(5): 1041. DOI: 10.3390/cells10051041.</mixed-citation><mixed-citation xml:lang="en">Robert J, Osto E, von Eckardstein A. The endothelium is both a target and a barrier of HDL’s protective functions. Cells. 2021; 10(5): 1041. DOI: 10.3390/cells10051041.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Soran H, Schofield JD, Durrington PN. Antioxidant properties of HDL. Front Pharmacol. 2015; 6: 222. DOI: 10.3389/fphar.2015.00222.</mixed-citation><mixed-citation xml:lang="en">Soran H, Schofield JD, Durrington PN. Antioxidant properties of HDL. Front Pharmacol. 2015; 6: 222. DOI: 10.3389/fphar.2015.00222.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Sphingosine-1-phosphate promotes barrier-stabilizing effects in human microvascular endothelial cells via AMPK-dependent mechanisms / S. Dennhardt, K.R. Finke, A. Huwiler [et al.] // BBA Mol Basis Dis. 2019; 1865: 774-781. DOI: 10.1016/j.bbadis.2018.12.022</mixed-citation><mixed-citation xml:lang="en">Sphingosine-1-phosphate promotes barrier-stabilizing effects in human microvascular endothelial cells via AMPK-dependent mechanisms / S. Dennhardt, K.R. Finke, A. Huwiler [et al.] // BBA Mol Basis Dis. 2019; 1865: 774-781. DOI: 10.1016/j.bbadis.2018.12.022</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Structure-function relationships of HDL in diabetes and coronary heart disease / M. Cardner, M. Yalcinkaya, S. Goetze [et al.] // JCI Insight. 2020; 5(1): e131491. DOI: 10.1172/jci.insight.131491</mixed-citation><mixed-citation xml:lang="en">Structure-function relationships of HDL in diabetes and coronary heart disease / M. Cardner, M. Yalcinkaya, S. Goetze [et al.] // JCI Insight. 2020; 5(1): e131491. DOI: 10.1172/jci.insight.131491</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">The apolipoprotein M/S1P Axis controls triglyceride metabolism and Brown fat activity / C. Christoffersen, C.K. Federspiel, A. Borup [et al.] // Cell Reports. 2018; 22:175–188. DOI: 10.1016/j.celrep.2017.12.029</mixed-citation><mixed-citation xml:lang="en">The apolipoprotein M/S1P Axis controls triglyceride metabolism and Brown fat activity / C. Christoffersen, C.K. Federspiel, A. Borup [et al.] // Cell Reports. 2018; 22:175–188. DOI: 10.1016/j.celrep.2017.12.029</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">The apolipoprotein A-I mimetic peptide, D-4F, alleviates ox-LDL-induced oxidative stress and promotes endothelial repair through the eNOS/HO-1 pathway / D. Liu, Z. Ding, M. Wu [et al.] // JMCC. 2017; 105: 77-88. DOI:10.1016/j.yjmcc.2017.01.017</mixed-citation><mixed-citation xml:lang="en">The apolipoprotein A-I mimetic peptide, D-4F, alleviates ox-LDL-induced oxidative stress and promotes endothelial repair through the eNOS/HO-1 pathway / D. Liu, Z. Ding, M. Wu [et al.] // JMCC. 2017; 105: 77-88. DOI:10.1016/j.yjmcc.2017.01.017</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Understanding myeloperoxidase-induced damage to HDL structure and function in the vessel wall: implications for HDL-based therapies / G. Marsche, J.T. Stadler, J. Kargl [et al.] // Antioxidants. 2022; 11: 556. DOI: 10.3390/antiox11030556</mixed-citation><mixed-citation xml:lang="en">Understanding myeloperoxidase-induced damage to HDL structure and function in the vessel wall: implications for HDL-based therapies / G. Marsche, J.T. Stadler, J. Kargl [et al.] // Antioxidants. 2022; 11: 556. DOI: 10.3390/antiox11030556</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Tan JT, Ng MK, Bursill CA. The role of high-density lipoproteins in the regulation of angiogenesis. Cardiovasc Res. 2015; 106(2): 184-93. DOI: 10.1093/cvr/cvv104</mixed-citation><mixed-citation xml:lang="en">Tan JT, Ng MK, Bursill CA. The role of high-density lipoproteins in the regulation of angiogenesis. Cardiovasc Res. 2015; 106(2): 184-93. DOI: 10.1093/cvr/cvv104</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">The compensatory enrichment of sphingosine-1-phosphate harbored on glycated high-density lipoprotein restores endothelial protective function in type 2 diabetes mellitus / X. Tong, Lv Pu, A.V. Mathew [et al.] // Cardiovasc Diabetol. 2014; 13:82. DOI: 10.1186/1475-2840-13-82.</mixed-citation><mixed-citation xml:lang="en">The compensatory enrichment of sphingosine-1-phosphate harbored on glycated high-density lipoprotein restores endothelial protective function in type 2 diabetes mellitus / X. Tong, Lv Pu, A.V. Mathew [et al.] // Cardiovasc Diabetol. 2014; 13:82. DOI: 10.1186/1475-2840-13-82.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Type 2 diabetes is associated with loss of HDL endothelium protective functions / T. Vaisar, E. Couzens, A. Hwang [et al.] // PLoS ONE. 2018; 13(3): e0192616. DOI: 10.1371/journal.pone.0192616</mixed-citation><mixed-citation xml:lang="en">Type 2 diabetes is associated with loss of HDL endothelium protective functions / T. Vaisar, E. Couzens, A. Hwang [et al.] // PLoS ONE. 2018; 13(3): e0192616. DOI: 10.1371/journal.pone.0192616</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Van der Vorst EPC. High-density lipoproteins and apolipoprotein A1. Vertebrate and invertebrate respiratory proteins, lipoproteins and other body fluid proteins. 2020; 399-420. DOI: 10.1007/978-3-030-41769-7_16</mixed-citation><mixed-citation xml:lang="en">Van der Vorst EPC. High-density lipoproteins and apolipoprotein A1. Vertebrate and invertebrate respiratory proteins, lipoproteins and other body fluid proteins. 2020; 399-420. DOI: 10.1007/978-3-030-41769-7_16</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Ucma/GRP inhibits phosphate-induced vascular smooth muscle cell calcifcation via SMAD-dependent BMP signaling / B.A. Willems, M. Furmanik, M.M.J. Caron [et al.] // Sci Rep. 2018; 8(1): 4961. DOI: 10.1038/s41598-018-23353-y</mixed-citation><mixed-citation xml:lang="en">Ucma/GRP inhibits phosphate-induced vascular smooth muscle cell calcifcation via SMAD-dependent BMP signaling / B.A. Willems, M. Furmanik, M.M.J. Caron [et al.] // Sci Rep. 2018; 8(1): 4961. DOI: 10.1038/s41598-018-23353-y</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
